Process for preparing purified interleukin-2
AssigneeSloan-Kettering Institute for Cancer Research
InventorsRoland Mertelsmann, Karl Welte, Salvatore Venuta
Life of this patent
Estimating the term…
Abstract
Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal huma This invention was made with support in part under Grants CA 08748, CA 22507, CA 25608, CA 20194, CA 21525, CA 31525, P01-CA-20194, AI 18 321-01, CA 23766 and CA 33050 awarded by the National Cancer Institute, National Institute of Health, DHEW. The government has certain rights in this invention.
Claims16
A process for preparing a human interleukin-2 purified to apparent homogeneity comprising:
- (a) treating human lympocytes so as to obtain a lymphocyte-conditioned medium which contains the human interleukin-2;
- (b) separately recovering from the lymphocyte-conditioned medium the proteinaceous components thereof, including the human interleukin-2;
- (c) subjecting the proteinaceous components so recovered to anion exchange chromatography so as to separate undesired, non-specific proteinaceous material from the human interleukin-2-containing proteinaceous components;
- (d) subjecting the resulting human interleukin-2-containing proteinaceous material to gel filtration chromatography so as to recover the human interleukin-2 and other proteinaceous material of about the same molecular weight;
- and
- (e) subjecting the human interleukin-2 and other proteinaceous material of about the same molecular weight to hydrophobic chromatography so as to obtain the human interleukin-2 purified to apparent homogeneity.
A process for purifying a human interleukin-2 which comprises subjecting partially purified lymphocyte conditioned medium to hydrophobic chromatography on Red agarose followed by Blue agarose.
In a process for the purification of a human interleukin-2, the improvement comprising the steps of isolating proteinaceous material consisting essentially of human interleukin-2 and non-specific proteinaceous material of about the same molecular weight as human interleukin-2 and subjecting said proteinaceous material to hydrophobic chromatography, thereby separating said human interleukin-2 from said non-specific proteinaceous material.
Dependencies are inferred from the claim text.